Signals were just the beginning. Fundz is what’s next.
Only Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Outro, a de-prescribing startup, raises $7M in pre-seed and seed funding to help patients safely discontinue antidepressants.
PRIVATEOct 08, 2026
Amount Raised
$7 Million
Round Type
Seed
BiotechnologyHealth CareMedical
Description
Outro, a de-prescribing startup, announced today that it has raised $7 million in pre-seed and seed funding. The company focuses on helping patients safely discontinue antidepressants by addressing withdrawal symptoms and providing structured tapering support. Outro employs healthcare professionals, including nurse practitioners like Kristen Massingill, who work with patients on medication reduction strategies. The funding will support the company's mission to improve the de-prescribing process and patient outcomes.
Company Information
Company
Outro
About
Outro is a de-prescribing startup that helps patients safely discontinue antidepressant medications through personalized tapering plans. The company works with healthcare practitioners to address withdrawal symptoms and provide tailored support during medication reduction. Outro was co-founded by psychiatry researcher Mark Horowitz and has raised $7 million in pre-seed and seed funding. The startup focuses on patient education and individualized approaches to antidepressant discontinuation.
Fundz sees it the moment Outro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
